{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:18:47Z","timestamp":1775157527476,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00520-011-1165-1","type":"journal-article","created":{"date-parts":[[2011,4,30]],"date-time":"2011-04-30T08:45:47Z","timestamp":1304153147000},"page":"941-949","source":"Crossref","is-referenced-by-count":11,"title":["Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice"],"prefix":"10.1007","volume":"20","author":[{"given":"Hind T.","family":"Hatoum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swu-Jane","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,1]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2003.08.118","volume":"21","author":"WC Mertens","year":"2003","unstructured":"Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373\u20131378. doi: 10.1200\/JCO.2003.08.118","journal-title":"J Clin Oncol"},{"key":"1165_CR2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449. doi: 10.1093\/annonc\/mdl137","journal-title":"Ann Oncol"},{"key":"1165_CR3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ncponc0132","volume":"2","author":"TH Oo","year":"2005","unstructured":"Oo TH, Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2:196\u2013201. doi: 10.1038\/ncponc0132","journal-title":"Nat Clin Pract Oncol"},{"key":"1165_CR4","volume-title":"Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat nodose ganglia","author":"Y Li","year":"2009","unstructured":"Li Y, Wu X, Rojas C (2009) Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat nodose ganglia. Annual American Society of Hematology Meeting, New Orleans"},{"key":"1165_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2009.10.002","volume":"626","author":"C Rojas","year":"2010","unstructured":"Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193\u2013199. doi: 10.1016\/j.ejphar.2009.10.002","journal-title":"Eur J Pharmacol"},{"key":"1165_CR6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003495-200464100-00006","volume":"64","author":"MA Siddiqui","year":"2004","unstructured":"Siddiqui MA, Scott LJ (2004) Palonosetron. Drugs 64:1125\u20131132. doi: 10.2165\/00003495-200464100-00006","journal-title":"Drugs"},{"key":"1165_CR7","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2165\/11200980-000000000-00000","volume":"69","author":"LP Yang","year":"2009","unstructured":"Yang LP, Scott LJ (2009) Palonosetron: in the prevention of nausea and vomiting. Drugs 69:2257\u20132278. doi: 10.2165\/11200980-000000000-00000","journal-title":"Drugs"},{"key":"1165_CR8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570\u20131577. doi: 10.1093\/annonc\/mdg417","journal-title":"Ann Oncol"},{"key":"1165_CR9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","volume":"98","author":"P Eisenberg","year":"2003","unstructured":"Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473\u20132482. doi: 10.1002\/cncr.11817","journal-title":"Cancer"},{"key":"1165_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124. doi: 10.1016\/S1470-2045(08)70313-9","journal-title":"Lancet Oncol"},{"key":"1165_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373\u2013383","journal-title":"J Chron Dis"},{"key":"1165_CR12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139. doi: 10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"key":"1165_CR13","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF (1998) What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690\u20131691. doi: 10.1001\/jama.280.19.1690","journal-title":"JAMA"},{"key":"1165_CR14","author":"YC Yeh","year":"2011","unstructured":"Yeh YC, McDonnell A, Klinger EV, Fowler B, Matta L, Voit D, Reddy P (2011) Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. doi: 10.1177\/1078155210366491","journal-title":"J Oncol Pharm Pract"},{"key":"1165_CR15","first-page":"1759","volume":"19","author":"E Perez","year":"2005","unstructured":"Perez E, Muss HB (2005) Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology 19:1759\u20131767","journal-title":"Oncology"},{"key":"1165_CR16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","volume":"330","author":"G Bonadonna","year":"2005","unstructured":"Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30\u00a0years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217. doi: 10.1136\/bmj.38314.622095.8F","journal-title":"BMJ"},{"key":"1165_CR17","first-page":"403","volume":"4","author":"T Grote","year":"2006","unstructured":"Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:403\u2013408","journal-title":"J Support Oncol"},{"key":"1165_CR18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00520-008-0535-9","volume":"17","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Canc 17:589\u2013594","journal-title":"Support Care Canc"},{"issue":"9","key":"1165_CR19","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/cncr.23364","volume":"112","author":"JD Herrington","year":"2008","unstructured":"Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080\u20132087","journal-title":"Cancer"},{"key":"1165_CR20","unstructured":"Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Risk of uncontrolled chemotherapy induced nausea and vomiting (CINV) with highly emetogenic chemotherapy and a triple combination anti-emetic prophylaxis regimen. Abtract accepted at 2011 Hematology\/Oncology Pharmacists Association Annual Meeting; March 23\u201326, Salt Lake City, Utah"},{"key":"1165_CR21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1078155207078137","volume":"13","author":"M Hamadani","year":"2007","unstructured":"Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A (2007) Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract 13:69\u201375. doi: 10.1177\/1078155207078137","journal-title":"J Oncol Pharm Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00520-011-1165-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T19:33:20Z","timestamp":1497900800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1165-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1165-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,1]]}}}